ROARABLE
FREE $100K
My Trading Account →
▾
Trading Profile Active
Active Trader
Verified Trader
⚡ My $100K Trading Account → ★ My Saved Watchlist →
🟢 My $100K Account → Today Screener Big Ideas Track Record 💰 $100K Arena 🎲 Predictions 🏛️ Insiders 8 Analysts
Stock Ratings / Health Care / DXR / dividends
MDAI (16) SRTS (41) SKIN (32) SNWV (51) ⌘ Pro Terminal →

Daxor Corporation (DXR) Dividend Safety Gauge & 10-Year DRIP Compounder

$9.00 -2.17% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $8.95

Daxor Corporation (DXR) carries a Roarable Rating of D (Sell) with 47/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

ROARABLE D • SELL / AVOID Cap $53.7M
📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card
⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on DXR Below — or Connect Your Own ChatGPT / Claude
🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is DXR stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
▼

As of 2026-11-03, Daxor Corporation (NASDAQ: DXR) is rated D (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 47/100 at a spot price of $9.00 (-2.17% 1D, market cap $53.7M). Pillar breakdown: Fundamental Cash Engine 12/20, Institutional 13F & Options Flow 3/20, SEC Balance-Sheet Forensics 13/20, FRED Macro Regime Fit 10/20, and Executive Insider Alignment 9/20. Across 1015 tracked Health Care issuers, DXR ranks #312 in composite RQD confidence.

✓ Pre-computed one-to-many AI Quant brief
🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does DXR compare to MDAI and SRTS in the Health Care sector?
▼

Within the Health Care sector (Medical/Dental Instruments), DXR carries a Roarable D (47/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of —. By comparison, MDAI (Spectral AI Inc. (Class A)) holds a E grade (16/100 RQD, P/E N/A, ROIC -35.0%, cap $49.2M) and SRTS (Sensus Healthcare Inc.) posts a D- grade (41/100 RQD, P/E N/A, ROIC -31.3%, cap $45.4M). Among the 5-stock peer group, SNWV leads on earnings multiple (3.8x) while SNWV leads on capital efficiency (67.3% ROIC).

✓ Pre-computed one-to-many AI Quant brief
🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for DXR?
▼

For Daxor Corporation (DXR), key quantitative strengths include Established market leader in Health Care with deep daily trading liquidity and sector rank #312 in Health Care, while primary risk factors center on Company executives have done more routine share selling than personal cash buying lately and Sensitive to high interest rates and tighter Federal Reserve market liquidity.. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief
🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).
INTERACTIVE SCENARIO DECK:
🛡️ Portfolio Crash X-Ray
EXT / AFTER-HRS: $8.95 (-0.58%)🧬 Disciplined Float (-0.40% YoY Shares)⚙️ Cash Engine: 12/20 (C-) • 0% FCF Margin
Verify 90D Bucket Audit →
📊 Historical Track Record Warning: Scores below 50 (47/100 · D) historically underperformed SPY in 71% of rolling 90-day windows (-5.9% avg 90D alpha vs SPY • 29.0% hit rate).
Audit Bucket Track Record →
RQD QUANT TACHOMETERSELL / AVOID • D
025507510047
Quant Analyst Panel Split (Battleground)
Cash
SEC
Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR RQD RADARRw D- · Rk D+
Cash (12)Whales (3)SEC (13)Macro (10)CEO (9)
Each axis scored 0–20
12M PRICE TARGET CONE-5% Base Target
$16 Bull$9 Base$7 Bear
📬 FREE DXR RATING-CHANGE & BRIEFING ALERTSManage / Unsubscribe
WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for DXR)Realized 20D OHLCV Swing Band: ±8.3%
Deterministic 5-Pillar Attribution (47/100 Composite)
🔍 WHY DXR SCORES 47/100 (D) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
▲ #1 Bullish Driver: SEC 10-K Forensic Risk+13/20 pts (28% of score)

Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 7/9

▲ #2 Bullish Driver: Cash Engine Quality+12/20 pts (26% of score)

SEC XBRL Trailing 12 Months: 0% FCF Margin ($1.5M FCF) & 52% Gross Margin

▼ #1 Drag / Risk Factor: Whale & Options Positioning4/20 pts (-16 pt drag)

Put hedging (50% put share) caps near-term gamma upside (-16 pts vs max)

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current
Q1 (-3Q)
55
Grade C$10.35-5.8% Next Q
Q2 (-2Q)
52
Grade C-$9.75-8.8% Next Q
Q3 (-1Q)
50
Grade C-$8.89+1.2% Next Q
Current
47
Grade D$9.00-5.9% Hist 90D α
Trajectory: C (55) → D (47)Full Audit →
⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

⚔️ Adversarial Opposing Case: What Could Spark a DXR Turnaround Squeeze

Gideon Ashmere Forensic Desk →

While DXR currently carries a cautious 47/100 (D) rating due to Whale & Options Positioning (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

🚀 Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

🚀 Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($10.39) and Max Pain ($9.45) forces dealer call-delta covering toward $15.50.

🚀 Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Disciplined Float (-0.40% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $DXR• $2.4M Crowd Pool • Kalshi / Polymarket Composite
Contract: “DXR Beats Next Quarter EPS Consensus (Upcoming Quarter) & Holds Above 200D SMA”
YES 47%NO 53%Trade / Inspect Odds →
CASH DIVIDEND + BUYBACK YIELD
1.8% Total Yield
0% Cash ($0.00/yr) + 1.8% Buybacks
PAYOUT SAFETY SPEEDOMETER
74/100 • REINVESTING IN GROWTH + BUYBACKS
FREE CASH FLOW PAYOUT RATIO
0% (100% Reinvested)
Retains cash flow for R&D and share repurchases
INTERACTIVE DRIP & SHAREHOLDER-YIELD COMPOUNDER (6.8% EST. ANNUAL)

$10,000 Compounded Over 10 Years → $19,307

Est. Year-10 Shareholder Yield: $348/yr
$10.7K
Yr 1
$11.4K
Yr 2
$12.2K
Yr 3
$13.0K
Yr 4
$13.9K
Yr 5
$14.8K
Yr 6
$15.8K
Yr 7
$16.9K
Yr 8
$18.1K
Yr 9
$19.3K
Yr 10
ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring DXR)

  • ✓Walkthrough of DXR's RQD Radar, SEC cash-conversion gap & downside invalidation levels
  • ✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
  • ✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
Join Founding VIP Waitlist (No Card Required) →$100K Arena
DXR // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -11.07%📐 HORIZONTAL RANGE
2026-11-03O $8.92H $9.20L $8.92C $9.00VOL 28.0K
RES: $12.48SUP: $8.35SMA50: $10.39SMA200: $10.67
$12.52$11.40$10.29$9.17$8.05RES $12.48SUP $8.35$9.002026-05-042026-06-172026-08-042026-09-182026-11-03
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

DXR Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 DXR Butterfly Map → + Track DXR →
Share Count & Dilution Monitor

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle
8.0%/yr Implied 5Y Growth

vs. +6.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger

No active Ellis Vennor swing setup published on DXR today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for DXR. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for DXR today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (DXR)

Health Care Rank #312 of 1015 ⚔️ MDAI vs DXR Full Matrix →

1. Head-to-Head Health Care Peer Comparison (DXR vs. MDAI, SRTS, SKIN, SNWV)

Industry: Medical/Dental Instruments (120 Tracked Issuers)

Across 1015 tracked Health Care securities in the Roarable RQD universe, Daxor Corporation (DXR) ranks #312 by composite RQD confidence (47/100, grade D) and #733 by equity capitalization ($53.7M). Within this direct 5-issuer industry benchmark cohort, SNWV leads on earnings valuation at 3.8x trailing P/E, while SNWV leads on capital efficiency and profitability with 67.3% ROIC and 77.1% gross margin. SNWV currently holds the highest overall quantitative score in the immediate peer group at 51/100 (D) compared with DXR at 47/100 (D).

Ticker / Company Roarable Grade RQD Score Trailing P/E Gross Margin ROIC 1D Change Market Cap Head-to-Head
DXR ACTIVE
Daxor Corporation
D 47/100 — — — -2.17% $53.7M Benchmark Subject
MDAI
Spectral AI Inc. (Class A)
E 16/100 — 45.4% -35.0% -0.65% $49.2M /mdai-vs-dxr →
SRTS
Sensus Healthcare Inc.
D- 41/100 — 43.2% -31.3% -0.36% $45.4M /srts-vs-dxr →
SKIN
SkinHealth Systems Inc. (Class A)
E 32/100 — 65.3% -26.9% +4.43% $64.7M /skin-vs-dxr →
SNWV
SANUWAVE Health Inc.
D 51/100 3.8x 77.1% 67.3% +13.59% $44.3M /snwv-vs-dxr →

2. DXR Fundamental Profitability, Capital Efficiency & Balance-Sheet Forensics

TRAILING 12M & FORWARD QUANTITATIVE SNAPSHOT

Daxor Corporation (DXR) operates in Medical/Dental Instruments (Health Care) with an equity capitalization of $53.7M, trailing P/E of N/A, forward P/E of N/A, and EV/EBITDA of N/A. Operating profitability registers a gross margin of —, operating margin of —, net profit margin of —, ROIC of —, and free cash flow yield of —, alongside an Altman Z-Score of N/A and Piotroski F-Score of N/A.

3. DXR Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is DXR stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-03, Daxor Corporation (NASDAQ: DXR) is rated D (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 47/100 at a spot price of $9.00 (-2.17% 1D, market cap $53.7M). Pillar breakdown: Fundamental Cash Engine 12/20, Institutional 13F & Options Flow 3/20, SEC Balance-Sheet Forensics 13/20, FRED Macro Regime Fit 10/20, and Executive Insider Alignment 9/20. Across 1015 tracked Health Care issuers, DXR ranks #312 in composite RQD confidence.

How does DXR compare to MDAI and SRTS in the Health Care sector?

Within the Health Care sector (Medical/Dental Instruments), DXR carries a Roarable D (47/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of —. By comparison, MDAI (Spectral AI Inc. (Class A)) holds a E grade (16/100 RQD, P/E N/A, ROIC -35.0%, cap $49.2M) and SRTS (Sensus Healthcare Inc.) posts a D- grade (41/100 RQD, P/E N/A, ROIC -31.3%, cap $45.4M). Among the 5-stock peer group, SNWV leads on earnings multiple (3.8x) while SNWV leads on capital efficiency (67.3% ROIC).

What are the biggest fundamental strengths and SEC risk factors for DXR?

For Daxor Corporation (DXR), key quantitative strengths include Established market leader in Health Care with deep daily trading liquidity and sector rank #312 in Health Care, while primary risk factors center on Company executives have done more routine share selling than personal cash buying lately and Sensitive to high interest rates and tighter Federal Reserve market liquidity.. Institutional options positioning shows a 50% call / 50% put premium split.

Where is DXR trading relative to its 50-day, 200-day, and 52-week technical levels?

DXR last traded at $9.00 (-2.17% on volume of 3,704 shares), positioning the stock -13.38% below its 50-day simple moving average ($10.39) and -15.65% below its 200-day simple moving average ($10.67). Across its 52-week range of $8.40 to $14.76, DXR sits at the 9.4% percentile with a 14-day RSI of 38.6 (NEUTRAL RANGE) and an implied next-earnings move of ±8.3% ($8.25 to $9.75).

Direct Sub-Reports: DXR RQD Cockpit DXR 12M Forecast DXR Earnings & Move DXR Dividends & DRIP DXR Insiders & 13F DXR Whale Options DXR Profit Sankey DXR News & Why
ROARABLE RATING BRIEF • RQD 47/100 (D) ✓ SEC XBRL & RQD VERIFIED

DXR — Daxor Corporation: What the Facts Mean to a Prospective Investor

Methodology: RQD v6.2 Deterministic 5-Pillar & SEC XBRL Audit
Updated: 2026-11-03

1. Roarable Rating Brief: What This Means to a Prospective Investor

Daxor Corporation (DXR) earns a live Roarable RQD composite score of 47/100, corresponding to a D letter grade (Roarable Sell) at a spot price of $9.00 (-2.17% 1D, market capitalization $53.7M).

  • Fundamental Cash Engine (12/20): Anchored by return on invested capital (ROIC) of —, gross margin of —, operating margin of —, and free cash flow yield of —.
  • Whale 13F & Options Flow (3/20) + Insider Conviction (9/20): Tracks institutional 13F accumulation, CBOE options call/put positioning, and SEC Form 4 / Congressional PTR filings.
  • Macro Regime Fit (10/20) + Forensic Balance Sheet (13/20): Incorporates a 1.00x equity beta, Altman Z-Score of N/A, Piotroski F-Score of N/A, and Debt/Equity of N/A.

2. Business Model, Unit Margins & SEC Financial Trajectory

Daxor Corporation (DXR) is a NASDAQ-listed issuer in the Health Care sector, within the Medical/Dental Instruments industry..1B. — describes its products, customers, or revenue model.

3. Institutional Bull vs. Bear Thesis & Valuation Tradeoff

  • 🐂 Primary Bull Case (D • RQD 47/100): Established market leader in Health Care with deep daily trading liquidity. Free cash flow yield of — and institutional whale pillar of 3/20. With Fundamental Cash Engine at 12/20 and Institutional Whale Flow at 3/20, sustained execution supports upside toward the upper end of the $8.40 – $14.76 52-week range.
  • 🐻 Primary Bear Case & Valuation Risk: Company executives have done more routine share selling than personal cash buying lately. Investors must weigh current valuation against — operating margins and a 1.00x macro beta.

4. 2nd-Order Butterfly Ripples & Key Questions to Watch

The sector assignment is Health Care and the industry is Medical/Dental Instruments; beyond these labels, no ripple mapping is supported by the sources.

  • Key Question #1: Can DXR sustain or expand its — operating margin and — ROIC against Medical/Dental Instruments peers over the next 4 quarters?
  • Key Question #2: Will free cash flow conversion (— FCF yield) strengthen balance-sheet liquidity (Altman Z-Score N/A) toward the $14.76 52-week high?
  • Key Question #3: How sensitive is DXR's equity valuation to Health Care capital spending cycles and macro interest-rate shifts (Beta 1.00x)?

DXR Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for Daxor Corporation (DXR) • Click "Debate This Headline" to argue it in the Roar Pit below

💬 Jump to DXR Debate Forum (3) ↓
🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE 3 Active Posts & Replies

DXR Bull vs. Bear Conversation Board — What's Your Call at $9.00?

🐂 67% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON DXR 🐻 33% BEARISH CONVICTION
1. Pick Your Side on DXR:
💡 Tip: Back up your call with a price target or RQD metric to get upvoted to the top.
AL AlphaFlow_Cap RQD DEBATE OPENER • Verified $100K Arena Trader 🐂 BULLISH 🎯 Target: $10.76 (+17.0%)
📌 Pinned Debate

Forensic balance sheet scores 13 of 20 with Piotroski F 6/9 and Altman Z 2.5, providing relative solvency support.

The street is overcomplicating Daxor Corporation (DXR). Forensic balance sheet scores 13 of 20 with Piotroski F 6/9 and Altman Z 2.5, providing relative solvency support.. With an RQD score of 47/100 (D) and Forensic Balance Sheet at 13/20, any positive earnings surprise or guidance raise forces underweight funds to chase above $9.94.

EarningsSniper 🐂 BULL

@MultipleCompression Shorting a 3/20 institutional whale-flow stock at $9.20 is dangerous when funds are rotating into Health Care.

MU MultipleCompression RQD DEBATE OPENER • Valuation Discipline 🐻 BEARISH 🎯 Target: $6.99 (-24.0%)
Spot @ $9.20

Institutional flow scores only 3 of 20 while ROIC and FCF yield are both 0%, leaving no cash return to anchor valuation.

Sitting on the sidelines or leaning short DXR above $9.20. Institutional flow scores only 3 of 20 while ROIC and FCF yield are both 0%, leaving no cash return to anchor valuation.. Until Fundamental Cash Engine (12/20) and FCF yield (0.0%) inflect higher, upside is capped near $14.76.

LIVE TAPE